GlassScriptPhysician profile
Amanda A Nanasy
NPI 1619283256
$190,088.22
in general payments reported to CMS, 2019-2025
23 companies · $34K in 2025
The $34K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $14K · 2021: $16K · 2022: $14K · 2023: $10K · 2024: $67K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $82K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $8,122 · Food and Beverage: $4,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $81,732.72 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,462.50 |
| Travel and Lodging | $8,122.06 |
| Food and Beverage | $4,893.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $134,197.65 | 2019-2025 | Dailies Total1, Total30, Precision 1 |
| Abb Con-Cise Optical Group LLC | $34,313.36 | 2019-2025 | Contact Lens, Spectacle Lenses |
| Abbvie INC. | $7,037.23 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $5,897.25 | 2019-2023 | Acuvue |
| Allergan, INC. | $4,549.88 | 2019-2022 | |
| Alcon Research LLC | $2,739.45 | 2022 | |
| Optos, INC. | $403.40 | 2019-2020 | |
| Coopervision INC. | $238.33 | 2019-2025 | Misight Contact Lens |
| Bausch & Lomb Americas INC. | $106.40 | 2022-2025 | Xiidra, Miebo, Infuse |
| Biotissue Holdings INC. | $102.34 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $86.10 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $69.70 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $66.61 | 2019-2021 | |
| Maculogix, INC. | $47.18 | 2019 | |
| Thea Pharma INC. | $43.16 | 2024-2025 | Iyuzeh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $35.12 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $31.65 | 2020-2022 | |
| Dompe US, INC. | $29.60 | 2025 | Oxervate |
| Harrow Eye, LLC | $26.00 | 2025 | Vevye |
| Amgen INC. | $19.26 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $18.75 | 2020 | |
| Shire North American Group INC | $15.62 | 2019 | |
| Oyster Point Pharma, INC. | $14.18 | 2024 | Ryzumvi, Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Nanasy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.